Although xCT inhibition as a regulator of ferroptosis is a potential strategy for cancer therapy, the potential targets of ferroptosis in the treatment of ovarian cancer in vivo and their mechanisms remain poorly understood. This evidence concerns the gene SLC7A11 and ovarian carcinoma.